• Quantum Biopharma's management commentary for the nine months ended September 30, 2026, emphasized development of lead multiple sclerosis compound Lucid-MS.
• Management reported a 19.48% stake in Unbuzzd, down from 19.84% at December 31, 2025, reflecting dilution.
• The Unbuzzd loan's maturity was extended to December 31, 2027, with all interest deferred until then; its annual rate remains 10%.
• A subsequent purchase of 1,500,000 Unbuzzd common shares at CAD 0.20 each increased the ownership stake to 19.87%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-005323), on November 12, 2026, and is solely responsible for the information contained therein.